Advertisement

Topics

Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada

08:18 EDT 10 Sep 2017 | ecancermedicalscience

Jan McKendrick speaks with ecancer at ESMO 2017 an investigation into the availability of cancer therapies across Europe and Canada, depending on different licensing and reimbursement processes. She describes how discord in national and international...

Original Article: Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada

NEXT ARTICLE

More From BioPortfolio on "Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...